Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044076 | 0.88 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTTSHR | |
| SCHEMBL6044131 | 0.86 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTHSD17B10 | |
| SCHEMBL6044013 | 0.83 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTHSD17B10 | |
| SCHEMBL6043957 | 0.80 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTHSD17B10 | |
| SCHEMBL20587629 | 0.77 | HCAR3 (0.66) | HCAR3RXFP1TP53MAPTTSHR | |
| SCHEMBL20587626 | 0.77 | HCAR3 (0.66) | HCAR3RXFP1TP53MAPTTSHR | |
| SCHEMBL6688047 | 0.77 | HCAR3 (0.77) | HCAR3RXFP1TP53MAPTHSD17B10 | |
| SCHEMBL6688059 | 0.75 | HCAR3 (0.60) | HCAR3RXFP1TP53MAPTTSHR | |
| SCHEMBL14092692 | 0.74 | HCAR3 (0.57) | HCAR3RXFP1TP53MAPTTSHR | |
| SCHEMBL241491 | 0.72 | HCAR3 (0.73) | HCAR3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4638447-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024188906-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |